Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Brivaracetam
Drug ID BADD_D00297
Description Brivaracetam is a racetam derivative of levetiracetam used in the treatment of partial-onset seizures. Brivaracetam binds SV2A with 20 times higher affinity than levetiracetam [A19184]. It is available under the brand name Briviact made by UCB. Briviact received FDA approval on February 19, 2016 [L760].
Indications and Usage Used as adjunctive therapy for partial-onset seizures in patients 16 years of age or older.
Marketing Status approved; investigational
ATC Code N03AX23
DrugBank ID DB05541
KEGG ID D08879
MeSH ID C482793
PubChem ID 9837243
TTD Drug ID D0CT4D
NDC Product Code 16812-009; 36998-0118; 50474-670; 50474-770; 50474-970; 52076-6268; 28877-0118; 71666-007; 50474-370; 82608-003; 50474-570; 64220-214; 69037-0055; 50474-470; 69766-031; 50474-870
UNII U863JGG2IA
Synonyms brivaracetam | 2-(2-oxo-4-propylpyrrolidin-1-yl)butanamide | (2S)-2-((4R)-2-oxo-4-propylpyrrolidin-1-yl)butanamide | 1-pyrrolidineacetamide, alpha-ethyl-2-oxo-4-propyl-, (alphaS,4R)- | UCB 34714 | UCB34714 | UCB-34714 | Briviact
Chemical Information
Molecular Formula C11H20N2O2
CAS Registry Number 357336-20-0
SMILES CCCC1CC(=O)N(C1)C(CC)C(=O)N
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Personality change19.05.01.006; 17.02.05.0190.000336%
Petit mal epilepsy17.12.04.0010.000336%Not Available
Psychomotor hyperactivity17.01.02.011; 19.11.02.0030.000125%Not Available
Psychotic behaviour19.03.01.003--Not Available
Rash23.03.13.0010.003337%Not Available
Respiratory depression22.02.01.010; 17.02.05.0470.000125%Not Available
Respiratory failure22.02.06.002; 14.01.04.0030.000249%
Restlessness17.02.05.021; 19.11.02.0020.000125%
Sedation17.02.04.0050.000909%Not Available
Seizure17.12.03.0010.013362%
Skin reaction23.03.03.013; 10.01.03.0190.000274%Not Available
Sleep disorder19.02.04.0010.000648%Not Available
Somnolence17.02.04.006; 19.02.05.0030.003761%
Speech disorder22.12.03.027; 19.19.02.002; 17.02.08.0030.000125%Not Available
Status epilepticus17.12.03.0050.000311%Not Available
Stress19.06.02.004--Not Available
Suicidal ideation19.12.01.0030.001619%
Tearfulness19.15.02.005--Not Available
Thrombocytopenia01.08.01.0020.000498%Not Available
Tic19.11.04.001; 17.02.05.0240.000125%Not Available
Tonic convulsion17.12.03.0110.000125%Not Available
Vertigo17.02.12.002; 04.04.01.0030.000125%
General physical health deterioration08.01.03.0180.000125%Not Available
Homicidal ideation19.05.01.0080.000274%Not Available
Balance disorder17.02.02.007; 08.01.03.0810.000398%Not Available
Affect lability19.04.01.001--Not Available
Myoclonic epilepsy17.12.03.0070.000249%Not Available
Adverse event08.06.01.0100.000461%Not Available
Mental disorder19.07.01.0020.000336%Not Available
Partial seizures17.12.03.0100.000560%Not Available
The 3th Page    First    Pre   3 4    Next   Last    Total 4 Pages